Aliases & Classifications for Hypoxia

Aliases & Descriptions for Hypoxia:

Name: Hypoxia 51 69

Summaries for Hypoxia

Novus Biologicals : 53 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to sarcomatoid renal cell carcinoma and cerebral hypoxia, and has symptoms including anoxemia, cachexia and cheyne-stokes respiration. An important gene associated with Hypoxia is HIF1A (Hypoxia Inducible Factor 1 Alpha Subunit), and among its related pathways/superpathways are Cellular Senescence and Development HGF signaling pathway. The drugs Dopamine and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, breast and brain, and related phenotypes are cardiovascular system and cellular

NINDS : 51 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
id Related Disease Score Top Affiliating Genes
1 sarcomatoid renal cell carcinoma 28.9 HIF1A MTOR VHL
2 cerebral hypoxia 12.3
3 polycythemia due to hypoxia 11.8
4 anoxia 11.4
5 pulmonary edema 11.0
6 brain ischemia 11.0
7 apnea of prematurity 11.0
8 methemoglobinemia 11.0
9 tempi syndrome 11.0
10 dementia 11.0
11 neonatal hypoxic and ischemic brain injury 10.9
12 asphyxia neonatorum 10.9
13 methemoglobinemia, type i 10.8
14 renal cell carcinoma 10.7
15 severe acute respiratory syndrome 10.7
16 pneumothorax, primary spontaneous 10.7
17 methemoglobinemia, type iv 10.7
18 exudative vitreoretinopathy 6 10.7
19 exudative vitreoretinopathy 4 10.7
20 exudative vitreoretinopathy 1 10.7
21 hantavirus pulmonary syndrome 10.7
22 exudative vitreoretinopathy 2, x-linked 10.7
23 congenital laryngeal palsy 10.7
24 chronic mountain sickness 10.7
25 exudative vitreoretinopathy 5 10.7
26 endotheliitis 10.7
27 cerebritis 10.5
28 ischemia 10.5
29 breast cancer 10.4
30 dominant hypophosphatemia with nephrolithiasis or osteoporosis 10.3 EGLN1 EPAS1
31 polycystic kidney disease 10.3
32 neuronitis 10.3
33 prostatitis 10.3
34 gtp cyclohydrolase 1-deficient dopa-responsive dystonia 10.3 HIF1A VHL
35 pancreatitis 10.3
36 atrioventricular septal defect 2 10.2 EGLN1 EPAS1 HIF1A VHL
37 central nervous system leiomyosarcoma 10.2 EPAS1 HIF1A VHL
38 prostate cancer 10.2
39 lung cancer 10.2
40 squamous cell carcinoma 10.2
41 acute posterior multifocal placoid pigment epitheliopathy 10.2 EGLN1 HIF1A HIF1AN VHL
42 intestinal impaction 10.2 EGLN1 EPAS1 HIF1A VHL
43 hepatocellular carcinoma 10.2
44 pancreatic cancer 10.2
45 glioma 10.2
46 cleft palate cardiac defect ectrodactyly 10.2 EPAS1 HIF1A VHL
47 glioblastoma 10.2
48 retinitis 10.2
49 adenocarcinoma 10.1
50 pulmonary hypertension 10.1

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:


anoxemia, cachexia, cheyne-stokes respiration, coughing, cyanosis, dyspnea, edema, fever, headache, hemoptysis, hoarseness, icterus, seizures, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, syncope, vertigo, chills, reduced consciousness/confusion, hyperoxia, motor symptom, skin symptoms, hot flushes, physical symptom, increased sweating, physical appearance, body

MGI Mouse Phenotypes related to Hypoxia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 CITED2 EGLN2 EGLN3 EGLN1 ARNT HIF1AN
2 cellular MP:0005384 10.39 CITED2 EGLN2 EGLN3 EGLN1 ARNT VHL
3 homeostasis/metabolism MP:0005376 10.38 CITED2 EGLN2 EGLN3 EGLN1 ARNT VHL
4 growth/size/body region MP:0005378 10.32 ARNT EGLN1 EGLN2 CITED2 VHL EPAS1
5 hematopoietic system MP:0005397 10.27 ARNT EGLN1 EGLN2 CITED2 VHL EPAS1
6 embryo MP:0005380 10.26 CITED2 EGLN2 EGLN3 EGLN1 ARNT VHL
7 immune system MP:0005387 10.23 ARNT EGLN1 EGLN2 CITED2 VHL EPAS1
8 mortality/aging MP:0010768 10.22 ARNT EGLN1 CITED2 VHL EPAS1 EGLN3
9 craniofacial MP:0005382 10.19 CITED2 EGLN2 EGLN1 ARNT VHL EGLN3
10 muscle MP:0005369 10.18 EGLN2 EGLN3 EGLN1 HIF1AN EPAS1 HIF1A
11 nervous system MP:0003631 10.06 ARNT EGLN1 CITED2 EPAS1 EGLN3 HIF1A
12 liver/biliary system MP:0005370 10.03 ARNT EGLN1 EGLN2 VHL EPAS1 EGLN3
13 normal MP:0002873 9.86 ARNT CITED2 VHL EP300 EGLN3 HIF1A
14 renal/urinary system MP:0005367 9.81 CITED2 EGLN1 ARNT VHL HIF1A EP300
15 respiratory system MP:0005388 9.61 CITED2 EGLN1 EPAS1 HIF1A EP300 MTOR
16 vision/eye MP:0005391 9.23 CITED2 VHL EPAS1 EGLN3 HIF1A EP300

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2 10102-43-9 145068
3
Levodopa Approved Phase 4 59-92-7 6047
4
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
5
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
6
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
7
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
8
Bosentan Approved, Investigational Phase 4,Phase 1 147536-97-8 104865
9
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2 58-61-7 60961
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Budesonide Approved Phase 4,Phase 1 51333-22-3 63006 5281004
12
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
13
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
14
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 437-38-7 3345
16
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
17
Acetylcysteine Approved, Investigational Phase 4,Early Phase 1 616-91-1 12035
18
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
19
Bromhexine Approved Phase 4 3572-43-8
20
Fexofenadine Approved Phase 4 83799-24-0 3348
21
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3 59467-70-8 4192
22
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
23
Dipyridamole Approved Phase 4 58-32-2 3108
24
Nicorandil Approved Phase 4 65141-46-0 47528
25
Nifedipine Approved Phase 4 21829-25-4 4485
26
Captopril Approved Phase 4 62571-86-2 44093
27
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
28
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
29
Bisoprolol Approved Phase 4 66722-44-9 2405
30
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
31
Memantine Approved, Investigational Phase 4 19982-08-2 4054
32
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
33
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
34
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
35
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1 22916-47-8 4189
36
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
37
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
38
Remifentanil Approved Phase 4 132875-61-7 60815
39
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
40
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
41
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
42
Cetirizine Approved Phase 4 83881-51-0 2678
43
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
44
Etomidate Approved Phase 4 33125-97-2 36339 667484
45
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
46
Meperidine Approved Phase 4,Phase 2 57-42-1 4058
47
Ranibizumab Approved Phase 4 347396-82-1 459903
48
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
49
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 5284616 6436030 46835353
50
Desflurane Approved Phase 4 57041-67-5 42113

Interventional clinical trials:

(show top 50) (show all 1066)
id Name Status NCT ID Phase
1 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4
2 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4
3 Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4
5 Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage Unknown status NCT01180192 Phase 4
6 Home Oxygen Therapy in Bronchiolitis Unknown status NCT01216553 Phase 4
7 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Unknown status NCT00560586 Phase 4
8 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4
9 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4
10 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4
11 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4
12 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
13 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4
14 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4
15 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed NCT02628106 Phase 4
16 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure Completed NCT00517725 Phase 4
17 Ambulatory Oxygen Effects on Muscles in COPD Completed NCT01722370 Phase 4
18 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4
19 Single High Dose Vitamin C, E in Severe Birth Asphyxia Completed NCT01743742 Phase 4
20 CPAP in SAHS Patients With Hypertension Completed NCT02398032 Phase 4
21 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4
22 Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Completed NCT02171910 Phase 4
23 Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring Completed NCT01327677 Phase 4
24 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4
25 Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Completed NCT01260662 Phase 4
26 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4
27 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
28 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
29 The Use of Statins for Myocardial Death Prevention Completed NCT00772564 Phase 4
30 Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study) Completed NCT01103336 Phase 4
31 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4
32 Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition Completed NCT01545479 Phase 4
33 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea and Healthy Controls. Completed NCT00291993 Phase 4
34 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4
35 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia Completed NCT01091571 Phase 4
36 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4
37 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4
38 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients Completed NCT01996124 Phase 4
39 Bispectral Index and Clinical Parameters Evaluation in Dental Procedures Completed NCT02671578 Phase 4
40 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4
41 Short Term Physiological Effects of Nasal High Flow Oxygen on Respiratory Mechanics Completed NCT02363920 Phase 4
42 Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel Completed NCT00637455 Phase 4
43 Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy Completed NCT02602743 Phase 4
44 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4
45 Helmet Ventilation in Acute Hypercapnic Respiratory Failure Completed NCT01645358 Phase 4
46 Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients Completed NCT00804349 Phase 4
47 Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00491803 Phase 4
48 Inhaled Nitric Oxide by Oxygen Hood in Neonates Completed NCT00732537 Phase 4
49 Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management Completed NCT01710891 Phase 4
50 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4

Search NIH Clinical Center for Hypoxia

Genetic Tests for Hypoxia

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

39
Endothelial, Breast, Brain, Lung, Prostate, Smooth Muscle, Heart

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 6466)
id Title Authors Year
1
Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. ( 28088075 )
2017
2
Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells. ( 28065858 )
2017
3
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. ( 28423608 )
2017
4
Hypoxia and the hypoxia-regulated transcription factor HIF-1I+ suppress the host defence of airway epithelial cells. ( 28409544 )
2017
5
BAG-1L Protects SH-SY5Y Neuroblastoma Cells Against Hypoxia/Re-oxygenation Through Up-Regulating HSP70 and Activating PI3K/AKT Signaling Pathway. ( 28523530 )
2017
6
RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. ( 28046107 )
2017
7
Immunoexpression of GADD45I^ in the myocardium of newborns experiencing perinatal hypoxia. ( 28214215 )
2017
8
Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1I+ and vascular endothelial growth factor. ( 28091613 )
2017
9
pH, Lactate, and Hypoxia: Reciprocity in Regulating High-Affinity Monocarboxylate Transporter Expression in Glioblastoma. ( 28092823 )
2017
10
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. ( 27913861 )
2017
11
Hypoxia inducible factor-1I+-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease. ( 27921309 )
2017
12
Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT. ( 28198519 )
2017
13
Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma. ( 28485478 )
2017
14
Sirtuin 6 suppresses hypoxia-induced inflammatory response in human osteoblasts via inhibition of reactive oxygen species production and glycolysis-A therapeutic implication in inflammatory bone resorption. ( 27534902 )
2017
15
Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. ( 28483998 )
2017
16
A simple method to induce hypoxia-induced vascular endothelial growth factor-A (VEGF-A) expression in T24 human bladder cancer cells. ( 27752923 )
2017
17
Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of HIF-1I+ protein stability. ( 28279976 )
2017
18
Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension. ( 27959409 )
2017
19
FGF11 induced by hypoxia interacts with HIF-1I+ and enhances its stability. ( 28027390 )
2017
20
Naringenin ameliorates hypoxia/reoxygenation-induced endoplasmic reticulum stress-mediated apoptosis in H9c2 myocardial cells: involvement in ATF6, IRE1I+ and PERK signaling activation. ( 27785700 )
2017
21
Novel lnc RNA regulated by HIF-1 inhibits apoptotic cell death in the renal tubular epithelial cells under hypoxia. ( 28420760 )
2017
22
Hypoxia-induced production of peptidylarginine deiminases and citrullinated proteins in malignant glioma cells. ( 27818200 )
2017
23
Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced pulmonary hypertension. ( 28409279 )
2017
24
Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1I+. ( 28089831 )
2017
25
Expression of hypoxia-induced factor-1 alpha in early-stage and in metastatic oral squamous cell carcinoma. ( 28381176 )
2017
26
Hypoxia drives the transition of human dermal fibroblasts to a myofibroblast-like phenotype via the TGF-I^1/Smad3 pathway. ( 27909731 )
2017
27
Ascorbic acid, but not dehydroascorbic acid increases intracellular vitamin C content to decrease Hypoxia Inducible Factor -1 alpha activity and reduce malignant potential in human melanoma. ( 28012930 )
2017
28
Differential expression of thioredoxin binding protein-2/Txnip in human placenta: Possible involvement of hypoxia in its suppression during early pregnancy. ( 27762463 )
2017
29
Intermittent hypoxia causes mandibular growth retardation and macroglossia in growing rats. ( 28153167 )
2017
30
Concomitant Lung Cancer and Gastrointestinal Stromal Tumor: First Report of Hypoxia Imaging With 18F-FAZA PET/CT. ( 28525452 )
2017
31
Correction: Intermittent Hypoxia Effect on Osteoclastogenesis Stimulated by Neuroblastoma Cells. ( 28085942 )
2017
32
Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension. ( 28522921 )
2017
33
Role of SGK1 for fatty acid uptake, cell survival and radioresistance of NCI-H460 lung cancer cells exposed to acute or chronic cycling severe hypoxia. ( 27251632 )
2016
34
Effects of experimental left varicocele repair on hypoxia-inducible factor-1I+ and vascular endothelial growth factor expressions and angiogenesis in rat testis. ( 27178282 )
2016
35
Hypoxia-Induced Inflammatory Chemokines in Subjects with a History of High-Altitude Pulmonary Edema. ( 26855492 )
2016
36
Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1I+ inA vitro. ( 27221674 )
2016
37
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. ( 26679155 )
2016
38
Hypoxia but not normoxia promotes Smoothened transcription through upregulation of RBPJ and Mastermind-like 3 in pancreatic cancer. ( 26655998 )
2016
39
Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain. ( 27216570 )
2016
40
Hypoxia-Responsive Mir-301a and Mir-301b Promote Radioresistance of Prostate Cancer Cells via Downregulating NDRG2. ( 27327120 )
2016
41
Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the Interleukin-1 receptor. ( 27215684 )
2016
42
Hypoxia Promotes Gastric Cancer Malignancy Partly through the HIF-1I+ Dependent Transcriptional Activation of the Long Non-coding RNA GAPLINC. ( 27729869 )
2016
43
Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1I+ is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. ( 26984380 )
2016
44
Acute Mountain Sickness Symptoms Depend on Normobaric versus Hypobaric Hypoxia. ( 27847819 )
2016
45
Increased Umbilical Cord PAI-1 Levels in Placental Insufficiency Are Associated with Fetal Hypoxia and Angiogenesis. ( 26903689 )
2016
46
Key Role of ROS in the Process of 15-Lipoxygenase/15-Hydroxyeicosatetraenoiccid-Induced Pulmonary Vascular Remodeling in Hypoxia Pulmonary Hypertension. ( 26871724 )
2016
47
E-cadherin increasing multidrug resistance protein 1 via hypoxia-inducible factor-1I+ contributes to multicellular resistance in colorectal cancer. ( 26219897 )
2016
48
Levels of interleukin-6, superoxide dismutase and malondialdehyde in the lung tissue of a rat model of hypoxia-induced acute pulmonary edema. ( 26998026 )
2016
49
A New Approach for On-Demand Generation of Various Oxygen Tensions for In Vitro Hypoxia Models. ( 27219067 )
2016
50
Effects of short-term hypoxia and seawater acidification on hemocyte responses of the mussel Mytilus coruscus. ( 27207025 )
2016

Variations for Hypoxia

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2
Show member pathways
12.8 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
3 12.65 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
4 12.3 ARNT EGLN1 EPAS1 HIF1A HIF1AN HIPK2
5
Show member pathways
12.13 EP300 HIF1A HIPK2 PSMA7
6
Show member pathways
12.1 EP300 HIF1A HIPK2 RORA
7 11.92 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
8 11.84 EP300 HIF1A MTOR
9 11.83 ARNT EGLN1 EP300 HIF1A HIF1AN
10
Show member pathways
11.79 ARNT EPAS1 HIF1A VHL
11 11.72 ARNT CITED2 EGLN1 EGLN3 EP300 HIF1A
12
Show member pathways
11.61 ARNT EP300 HIF1A
13 11.56 HIF1A MTOR TIGAR
14 11.39 ARNT EP300 HIF1A
15 11.38 ARNT EGLN1 HIF1A HIF1AN
16
Show member pathways
11.36 ARNT CITED2 EGLN3 EP300 EPAS1 HIF1A
17 11.29 ARNT EGLN1 EGLN2 EP300 HIF1A HIF1AN
18 10.94 ARNT HIF1A HIF1AN HIF3A VHL
19 10.82 EPAS1 VHL
20 10.81 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
21 10.53 HIF1A HIF1AN

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 transcription factor complex GO:0005667 9.56 ARNT EP300 EPAS1 HIF1A
3 nucleoplasm GO:0005654 9.53 ARNT CITED2 EGLN2 EGLN3 EP300 EPAS1
4 RNA polymerase II transcription factor complex GO:0090575 9.33 ARNT HIF1A HIPK2
5 cytosol GO:0005829 10.1 EGLN1 EGLN3 EP300 EPAS1 HIF1A HIF1AN

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.99 CITED2 EP300 EPAS1 HIF1A HIF3A HIPK2
2 positive regulation of transcription, DNA-templated GO:0045893 9.98 ARNT CITED2 EP300 HIF1A HIPK2 RORA
3 post-translational protein modification GO:0043687 9.93 EPAS1 HIF1A HIF3A PSMA7 VHL
4 angiogenesis GO:0001525 9.89 EPAS1 HIF1A HIF3A RORA
5 positive regulation of endothelial cell proliferation GO:0001938 9.76 ARNT HIF1A MTOR
6 cellular response to hypoxia GO:0071456 9.7 EPAS1 HIF1A HIPK2 HYOU1 MTOR RORA
7 positive regulation of vascular endothelial growth factor production GO:0010575 9.65 ARNT HIF1A RORA
8 embryonic placenta development GO:0001892 9.63 ARNT EPAS1 HIF1A
9 mRNA transcription from RNA polymerase II promoter GO:0042789 9.62 ARNT HIF1A
10 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.61 ARNT HIF1A
11 positive regulation of glycolytic process GO:0045821 9.61 ARNT HIF1A
12 response to hypoxia GO:0001666 9.61 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
13 iris morphogenesis GO:0061072 9.57 HIF1A HIPK2
14 oxygen homeostasis GO:0032364 9.55 EGLN1 HIF1A
15 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.54 ARNT EPAS1 HIF1A
16 voluntary musculoskeletal movement GO:0050882 9.52 HIPK2 MTOR
17 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.5 EGLN1 EGLN2 EGLN3
18 positive regulation of hormone biosynthetic process GO:0046886 9.49 ARNT HIF1A
19 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.43 CITED2 HIF1AN VHL
20 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.4 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
21 transcription, DNA-templated GO:0006351 10.27 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
22 regulation of transcription, DNA-templated GO:0006355 10.26 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
23 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.06 ARNT CITED2 EGLN1 EP300 EPAS1 HIF1A
24 oxidation-reduction process GO:0055114 10.05 EGLN1 EGLN2 EGLN3 HIF1AN HIGD1A P4HTM
25 negative regulation of apoptotic process GO:0043066 10 CITED2 HIF1A HIGD1A HYOU1 VHL

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.89 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
2 transcription factor binding GO:0008134 9.85 ARNT EP300 EPAS1 HIF1A RORA VHL
3 protein dimerization activity GO:0046983 9.78 ARNT EPAS1 HIF1A HIF3A
4 iron ion binding GO:0005506 9.72 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 EGLN1 EGLN2 EGLN3 P4HTM
6 histone acetyltransferase binding GO:0035035 9.61 CITED2 EPAS1 HIF1A
7 dioxygenase activity GO:0051213 9.55 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
8 oxygen sensor activity GO:0019826 9.46 EGLN2 HIF1AN
9 peptidyl-proline 4-dioxygenase activity GO:0031545 9.43 EGLN1 EGLN2 EGLN3
10 L-ascorbic acid binding GO:0031418 9.26 EGLN1 EGLN2 EGLN3 P4HTM
11 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM

Sources for Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....